Byetta Byetta (exenatide) is structurally similar to glucagon-like peptide (GLP-1) but has a longer duration of action
Incretins based therapy (glucagon like peptide 1 receptor agonists and DPP-4 inhibitors) have also been tried in PPDM-A, however, incretins can precipitate AP and they are more likely to be associated with gastro-intestinal side effects so preferably avoided in the treatment of PPDM-A[76,77]
Drug approvals, trial data, prices and programs reflect the situation as of May 2026 and can change
The secondary mass resolution was set at 15000@m/z 200, with an AGC target of 1e6, a secondary maximum IT of 25 ms, HCD as the MS2 activation type, an isolation window of 20 Th, and a normalized collision energy of 32 98,99
Start Your GLP-1 Journey Without Insurance Today Ready to take the next step